Abstract:Abstract Background Tofacitinib is a rapidly acting Janus kinase (JAK) inhibitor with several case series reporting effectiveness in patients with acute severe ulcerative colitis (ASUC). However, there remains a paucity of prospective data evaluating its efficacy and rapidity of onset in ASUC. Methods The TRIUMPH study is a phase 4 prospective interventional trial of tofacitinib in ASUC conducted in five hospitals across Canada (Clinicaltrials.gov: NCT04925973). Patients with ASUC (biologic naïve and experienced) refractory to three days of intravenous corticosteroids (Modified Truelove-Witts Severity Index [MTWSI] > 10 despite steroids) were eligible for enrollment. Patients were treated with tofacitinib 10mg bid and assessed daily while in hospital. The primary outcome was day 7 clinical response (MTWSI reduction of > 3 from baseline and < 10). Secondary outcomes included rapidity of clinical and biomarker improvements over the first 7 days, colectomy over the course of one year, and corticosteroid-free clinical remission (total Mayo score < 2), endoscopic improvement (endoscopic Mayo score 0 or 1), and adverse events at 3, 6, and 12 months. Results This is an interim analysis as the study has been fully recruited with six-month follow-up available for all participants. 24 patients with ASUC were recruited and received tofacitinib 10mg bid. The mean total baseline Mayo score was 10.1 (SD 1.4) and all patients had a baseline Mayo endoscopic subscore of 2 (25%, 6/24) or 3 (75%, 18/24). One third of the patients (8/24) had previous anti-TNF failure. Day 7 clinical response was achieved in 58.3% (14/24) patients. The mean number of days to achieve clinical response was 2.4 days (SD 1.3). Marked reduction in C-reactive protein was observed in responders as soon as one day after tofacitinib initiation compared to non-responders (Figure 1). Colectomy occurred in 16.7% (4/24) patients by day 7 and 25% (6/24) by six months. At six months, 45.8% (11/24) patients remained on tofacitinib (including 78.6% (11/14) of day 7 responders), with 33.3% (8/24) having achieved endoscopic improvement and corticosteroid-free clinical remission. A total of six patients reported adverse events, one of which was considered severe (stroke at day 3 after initiation of tofacitinib). Conclusion Tofacitinib may be an effective induction strategy in patients hospitalized with steroid-refractory ASUC. Randomized controlled trials are needed to compare JAK inhibitors with infliximab for steroid refractory ASUC.

Tofacitinib for the treatment of refractory immune checkpoint inhibitor associated immune nephritis

Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study

Tofacitinib for Treatment in Immune-Mediated Myocarditis: the First Reported Cases

Case Report: Treatment for steroid-refractory immune-related myocarditis with tofacitinib

Therapeutic effects of tofacitinib on steroid-resistant immune checkpoint inhibitor-associated myocarditis

Tofacitinib in kidney transplantation

The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice

Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going

Tofacitinib for the Treatment of Antineutrophil Cytoplasm Antibody-Associated Vasculitis: a Pilot Study

Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme

Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib Treatment.

A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis

Safety and effectiveness of Janus kinase inhibitors in the management of inflammatory bowel disease following liver transplantation

DOP46 Tofacitinib for hospitalized acute severe Ulcerative Colitis – the TRIUMPH study

Tofacitinib As an Alternative Therapy for Refractory Intestinal Behçet’s Syndrome

Long-Term Outcome of Tofacitinib Treatment for Systemic Autoimmune Disease-Associated Refractory Scleritis

Tofacitinib for the treatment of severe rare skin diseases: a narrative review

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

P1024 The current role of Tofacitinib in acute severe ulcerative colitis in adult patients: A systematic review and pooled analysis

Targeting JAK3 in kidney transplantation: current status and future options

Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases